Verisante Technology, Inc. Receives the 2014 North American Technology Innovation Leadership of the Year Award from Frost & Sullivan

http://finance.yahoo.com/news/verisante-technology-inc-receives-2014-130000448.html

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 20, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has been honoured by Frost & Sullivan with the 2014 North American Technology Innovation Leadership of the Year Award for In Vivo Cancer Detection for its product, Verisante Aura™, a device for the detection of skin cancer.

"Verisante is pleased to accept the recognition of Aura™ as an innovative and disruptive technology that can make a positive impact on healthcare outcomes for skin cancer patients," said Thomas Braun, President and CEO. "As more Aura™ units are placed in clinics we believe this innovative technology can become part of the standard of care for assisting doctors in monitoring and diagnosing skin cancer."

Frost & Sullivan follows a 10-step process to evaluate candidates and assess their fit with its best-practice criteria. Frost & Sullivan's global network of consultants and analysts are asked to monitor, target, analyze and screen creative practices within their regions and to confer with their industry peers. An independent board of advisors considers the findings in order to choose the company that excels in its industry above all others in customer value leadership. Based on its analysis of the in vivo cancer detection market, Frost & Sullivan recognized Verisante as the leader for its commitment to innovation and technology excellence.

"Aura™ has a unique competitive advantage in the marketplace as it is capable of providing almost instantaneous information about the biochemical nature of a skin lesion," notes Frost & Sullivan Industry Analyst, Darshana De. "This advantage, and the potential for the same technology to be used for the detection of lung, colon and cervical cancer, differentiates Verisante as a leader in technology innovation."

Frost & Sullivan has more than 50 years of experience in business and is a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies.

About Frost & Sullivan

Frost & Sullivan enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. We leverage 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from over 40 offices on six continents.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Contact:

Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com
YouTube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante